Received Jul 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
they were planning on administering Boostrix/possible administration after temperature excursion; This non-serious case was reported by a nurse via call center representative and described the occurrence of intercepted product storage error in a patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 14-JUL-2025, the patient did not receive Boostrix. The patient had intercepted product storage error (Verbatim: they were planning on administering Boostrix/possible administration after temperature excursion). The outcome of the intercepted product storage error was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 14-JUL-2025 A nurse practitioner called in to request data about the stability of boostrix and Infanrix after an excursion, stated that they were planning on administering boostrix which led to intercepted product storage error. During the call, it was incredibly difficult to understand the conversation due to technical issues. The possible event was filed with the limited data that was able to be collected, although it was important to clarify that the dose was not administered, but being planned on being administered. The vaccine administration facility was the same as primary reporter.